Measured GFR at baseline, 6 months, 1 year, 2 years, and 3 years (primary long-term outcome) in the study group as a whole (overall), and in the 2 subgroups with CKD stage 3b and 4 considered separately, according to treatment with octreotide-LAR or placebo.

NIAID Data Ecosystem2026-03-11 收录

数据链接：

https://figshare.com/articles/dataset/Measured_GFR_at_baseline_6_months_1_year_2_years_and_3_years_primary_long-term_outcome_in_the_study_group_as_a_whole_overall_and_in_the_2_subgroups_with_CKD_stage_3b_and_4_considered_separately_according_to_treatment_with_octreotide-LAR_or_placebo_/7959650 数据链接链接失效反馈

官方服务：

资源简介：

Measured GFR at baseline, 6 months, 1 year, 2 years, and 3 years (primary long-term outcome) in the study group as a whole (overall), and in the 2 subgroups with CKD stage 3b and 4 considered separately, according to treatment with octreotide-LAR or placebo.

创建时间：

2019-04-05

Measured GFR at baseline, 6 months, 1 year, 2 years, and 3 years (primary long-term outcome) in the study group as a whole (overall), and in the 2 subgroups with CKD stage 3b and 4 considered separately, according to treatment with octreotide-LAR or placebo.

资源简介：

相关数据集